125 related articles for article (PubMed ID: 35259461)
1. DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation.
Leung AWY; Chen KTJ; Ryan GM; Anantha M; Wretham N; Nosrati Z; Heroux D; Wang L; Chow N; Dai Z; Bally MB
J Control Release; 2022 May; 345():75-90. PubMed ID: 35259461
[TBL] [Abstract][Full Text] [Related]
2. Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor.
Leung AWY; Anantha M; Dragowska WH; Wehbe M; Bally MB
J Control Release; 2018 Sep; 286():1-9. PubMed ID: 30016731
[TBL] [Abstract][Full Text] [Related]
3. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
4. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
Lim HJ; Masin D; Madden TD; Bally MB
J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a novel flavopiridol formulation for treatment of acute myeloid leukemia.
Chen KTJ; Militao GGC; Anantha M; Witzigmann D; Leung AWY; Bally MB
J Control Release; 2021 May; 333():246-257. PubMed ID: 33798663
[TBL] [Abstract][Full Text] [Related]
6. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
[TBL] [Abstract][Full Text] [Related]
7. Formation of transition metal-doxorubicin complexes inside liposomes.
Abraham SA; Edwards K; Karlsson G; MacIntosh S; Mayer LD; McKenzie C; Bally MB
Biochim Biophys Acta; 2002 Sep; 1565(1):41-54. PubMed ID: 12225851
[TBL] [Abstract][Full Text] [Related]
8. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
9. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
[TBL] [Abstract][Full Text] [Related]
10. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.
Wehbe M; Anantha M; Shi M; Leung AW; Dragowska WH; Sanche L; Bally MB
Int J Nanomedicine; 2017; 12():4129-4146. PubMed ID: 28615941
[TBL] [Abstract][Full Text] [Related]
11. A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor.
Zhao Y; May JP; Chen IW; Undzys E; Li SD
Pharm Res; 2015 Oct; 32(10):3261-8. PubMed ID: 25964047
[TBL] [Abstract][Full Text] [Related]
12. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M
Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
14. Ni2+-mediated mitoxantrone encapsulation: improved efficacy of fast release formulation.
Cui J; Li C; Wang L; Wang C; Yang H; Li Y; Zhang L; Zhang L; Guo W; Liang M
Int J Pharm; 2009 Feb; 368(1-2):24-30. PubMed ID: 18973800
[TBL] [Abstract][Full Text] [Related]
15. Freeze-drying cycle optimization for the rapid preservation of protein-loaded liposomal formulations.
Hussain MT; Forbes N; Perrie Y; Malik KP; Duru C; Matejtschuk P
Int J Pharm; 2020 Jan; 573():118722. PubMed ID: 31705976
[TBL] [Abstract][Full Text] [Related]
16. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a liposomal copper(II)-quercetin formulation suitable for parenteral use.
Chen KTJ; Anantha M; Leung AWY; Kulkarni JA; Militao GGC; Wehbe M; Sutherland B; Cullis PR; Bally MB
Drug Deliv Transl Res; 2020 Feb; 10(1):202-215. PubMed ID: 31482519
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation.
Webb MS; Boman NL; Wiseman DJ; Saxon D; Sutton K; Wong KF; Logan P; Hope MJ
Antimicrob Agents Chemother; 1998 Jan; 42(1):45-52. PubMed ID: 9449259
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity.
Pereira S; Egbu R; Jannati G; Al-Jamal WT
Int J Pharm; 2016 Nov; 514(1):150-159. PubMed ID: 27863659
[TBL] [Abstract][Full Text] [Related]
20. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver.
Lim HJ; Parr MJ; Masin D; McIntosh NL; Madden TD; Zhang G; Johnstone S; Bally MB
Clin Cancer Res; 2000 Nov; 6(11):4449-60. PubMed ID: 11106266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
